10-K: MaxCyte Reports FY2024 Results, Highlights Strategic Growth Initiatives

MaxCyte's 10-K filing summarizes the company's financial performance for 2024, highlighting its cell engineering technology and strategic platform license agreements.

Summary

• MaxCyte, Inc., a cell engineering and life sciences company, filed its 10-K report for the fiscal year ended December 31, 2024.
• The company has incurred significant losses since its inception and expects to continue incurring losses in the foreseeable future.
• MaxCyte's revenue is primarily generated from the sale and licensing of its instruments and single-use disposable processing assemblies (PAs).
• The company's business is dependent on the adoption of its products by biopharmaceutical companies and academic institutions for cell-based therapeutics research and development.
• MaxCyte faces competition from existing and future competitors in the life sciences market.
• The company's strategic platform license (SPL) agreements are crucial for its business, and failure to maintain or expand these agreements could adversely affect its operations.
• Customer milestones may not be achieved, which could negatively impact the company's business and stock price.
• MaxCyte depends on third-party suppliers for high-quality components and raw materials, and shortages could harm its ability to meet customer demand.
• The company has limited experience manufacturing PAs and may face challenges in consistently producing high-quality commercial quantities.
• MaxCyte's results of operations may be harmed if it cannot accurately forecast customer demand and manage inventory.
• The company may need additional funding and may be unable to raise capital when needed, potentially requiring it to delay or abandon commercialization efforts.
• The aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates as of June 28, 2024 was approximately $407.2 million.
• As of March 7, 2025, the registrant had 106,027,733 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the acquisition of SeQure Dx and the potential of SPL agreements, the company is still incurring losses and faces several risks and challenges.

Positives

• Acquisition of SeQure Dx expands service offerings.
• SPL agreements provide potential for significant milestone and commercial payments.
• Recurring revenue model provides high visibility.
• Leadership team and workforce have deep domain knowledge.
• Proprietary technology platform can unlock the potential of cell-based therapeutics.
• Comprehensive, high-performance transfection platform.
• Capitalizing on the large and growing next-generation cell therapy market.
• Innovative SPL agreement business model focused on value creation and shared success.
• The company's Flow Electroporation technology is used by one of its SPL customers to engineer the first ex-vivo cell therapy approved by the FDA in December 2023.

Negatives

• Significant losses since inception and expected to continue.
• Limited number of product offerings approved for commercial sale.
• Highly dependent on a limited number of product offerings.
• SPL agreements and research and clinical licenses may be terminated at the option of its customers at any time.
• The company may be unable to compete successfully against its existing or future competitors.
• The company's business currently depends significantly on research and development spending by biopharmaceutical companies, a reduction in which could limit demand for its products and adversely affect its business and operating results.
• The company's international operations may raise additional risks, which could have an adverse effect on its operating results.
• The company's customers have significant discretion in determining when and whether to make announcements, if any, about the status of their clinical developments and timelines for advancing collaborative programs, and the price of its common stock may decline as a result of announcements of unexpected results or developments.
• The company's customers may not achieve projected development and regulatory milestones and other anticipated key events in the expected timelines or at all, or may discontinue some or all of their programs, which could have an adverse impact on its business and could cause the price of its common stock to decline.
• The company has depended on a limited number of customers for its revenue, the loss of any of which could have an adverse impact on its business.
• The company may engage in future acquisitions that could disrupt its business, cause dilution to its stockholders and harm its financial condition and operating results.
• The company depends on continued supply of high-quality components and raw materials for its ExPERT instruments and PAs from third-party suppliers, and if shortages of these components or raw materials arise, it may not be able to secure enough components to build new products to meet customer demand or it may be forced to pay higher prices for these components.
• The company has limited experience manufacturing its PAs and may be unable to manufacture its PAs in high-quality commercial quantities successfully and consistently to meet demand, which could limit its growth.
• The company's results of operations will be harmed if it is unable to accurately forecast customer demand for its products and manage its inventory.
• The company's systems are complex in design and may contain defects that are not detected until deployed by its customers, which could harm its reputation, increase its costs and reduce its sales.
• The company's FDA Master File, and equivalent Master and Technical Files in foreign jurisdictions, are an important part of its strategic offering which allows its SPL customers to expedite their cellular therapies or other biologics into and through clinical development.
• The company may need additional funding and may be unable to raise capital when needed, which could force it to delay, reduce, eliminate, or abandon its commercialization efforts or product development programs.
• The price of the company's common stock is likely to be volatile and may fluctuate due to factors beyond its control.
• The requirements of being a public company in the United States may strain the company's resources, increase its operating costs, divert management's attention, and affect its ability to attract and retain qualified board members or executive officers.
• The company's certificate of incorporation designates the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between the company and its stockholders, which will restrict its stockholders' ability to choose the judicial forum for disputes with the company or its directors, officers or employees.

Risks

• Inability to achieve or maintain profitability.
• Dependence on a limited number of product offerings.
• Failure to successfully execute growth strategy.
• Inaccurate market opportunity estimates and forecasts.
• Dependence on adoption of products by biopharmaceutical companies and academic institutions.
• Inability to compete successfully against existing or future competitors.
• Reliance on research and development spending by biopharmaceutical companies.
• Risks associated with international operations.
• Failure to offer high-quality customer service.
• Failure of customers to meet contractual obligations.
• Customers may not achieve projected development and regulatory milestones.
• Undesirable side effects or other properties of customer products.
• Pursuit of collaborations or licensing arrangements that may fail.
• Engaging in future acquisitions that could disrupt business.
• Dependence on third-party suppliers for components and raw materials.
• Limited experience manufacturing PAs.
• Inability to accurately forecast customer demand and manage inventory.
• Systems may contain defects not detected until deployed.
• Failure to successfully expand commercial operations.
• Failure to expand peer-reviewed articles and brand awareness.
• Delays in filing or obtaining acceptance of FDA Master File.
• Changes in tariffs or other government trade policies.
• Governmental export controls.
• Stringent and changing data privacy and security laws.
• Exposure to U.S. and foreign anti-corruption and anti-money laundering laws.
• Exposure to U.S. federal and state healthcare laws and regulations.
• Exposure to environmental regulation and health and safety matters.
• Need for additional funding and potential inability to raise capital.
• Results of operations and liquidity needs could be materially and adversely affected by market fluctuations, an economic downturn, inflation, increases in interest rates, and other macroeconomic conditions.
• Operating results may fluctuate significantly.
• Ability to use net operating losses may be subject to limitations.
• Changes in tax laws or regulations.
• A pandemic, epidemic, outbreak of an infectious disease or other public health emergency in the United States or worldwide could adversely affect our business and the businesses of our partners.
• If our information technology systems, or those of third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
• The company is highly dependent on its senior management team and key personnel and its business could be harmed if it is unable to attract and retain personnel necessary for its success.
• The company may face exposure to foreign currency exchange rate fluctuations.
• The company's ability to compete and the success of its business could be jeopardized if it is unable to protect its intellectual property adequately.
• The company may be sued by third parties for alleged infringement of their proprietary rights, which could be costly and time-consuming and which could limit its ability to use certain technologies in the future or to develop future products.
• Changes in U.S. patent law could diminish the value of patents in general, thereby impairing the company's ability to protect its products.
• The company may be obligated to disclose its proprietary technology to its customers, which may limit its ability to protect its intellectual property.
• The company's common stock is traded on two separate stock markets and investors seeking to take advantage of price differences between such markets may create unexpected volatility in its share price; in addition, investors may not be able to easily move shares for trading between such markets.
• The price of the company's common stock is likely to be volatile and may fluctuate due to factors beyond its control.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the company's business, the price of its common stock and its trading volume could decline.
• The requirements of being a public company in the United States may strain the company's resources, increase its operating costs, divert management's attention, and affect its ability to attract and retain qualified board members or executive officers.
• Increasing scrutiny and evolving expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.
• Future sales of the company's common stock in the public market could cause its share price to fall.
• Because the company does not expect to pay dividends on its common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain.
• Provisions in the company's governing documents will require disclosure of information about stockholders that would not otherwise be required to be disclosed under applicable U.S. state or federal laws.
• The company is an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.
• If the company fails to maintain an effective system of internal control over financial reporting, it may not be able to accurately report its financial results or prevent fraud.
• Anti-takeover provisions in the company's charter documents and under Delaware law could make an acquisition of the company more difficult, limit attempts by its stockholders to replace or remove its current management and limit the market price of its common stock.
• The company's certificate of incorporation designates the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between the company and its stockholders, which will restrict its stockholders' ability to choose the judicial forum for disputes with the company or its directors, officers or employees.

Future Outlook

The company expects to continue incurring net losses as it focuses on growing commercial sales of its products, scaling its manufacturing operations, and continuing research and development efforts. The company believes that its existing cash balances and cash receipts generated from sales of its products will be sufficient to meet its anticipated cash requirements for the foreseeable future.

Industry Context

The regenerative medicine sector, which consists of gene, cell, and tissue-based therapeutic developers raised an aggregate of $15.2 billion in 2024 and that, as of December 2024, there were more than 1,950 active clinical trials focused on regenerative and advanced medicine, which includes gene therapy, cell-based immuno-oncology, cell therapy and tissue engineering.

Comparison to Industry Standards

• MaxCyte primarily competes against products marketed by Lonza Group AG, Thermo Fisher Scientific Inc.(NYSE: TMO), Miltenyi Biotec, Bio-Rad Laboratories, Inc. (NYSE: BIO) and Harvard Bioscience, Inc. (Nasdaq: HBIO), as well as several other smaller companies, including spinouts from academic labs.
• Some of these companies may have substantially greater financial and other resources than MaxCyte, including larger research and development staff or more established sales forces.
• Other competitors are in the process of developing novel technologies for the life sciences market which may lead to products that rival or replace MaxCyte's products.

Related Party Transactions

• Effective January 1, 2024, the Company entered into a consulting agreement with a member of the Board of Directors to provide consulting services to the Company for a 12-month period for an amount not to exceed $150.
• During the year ended December 31, 2024, the Company sold $86 in products to a customer whose Chief Executive Officer is a member of the Company’s Board of Directors.
• During the year ended December 31, 2024, the Company sold less than $1 in products to a customer whose Board of Directors includes a member who also serves on the Company’s Board of Directors.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings; stock price volatility.
• Employees: Potential for job security and career growth; impact of equity awards.
• Customers: Access to innovative cell engineering technologies; potential for improved therapeutic development.
• Suppliers: Continued business relationships; potential for increased demand.
• Creditors: Financial stability and ability to meet obligations.

Next Steps

• Continue to invest in technology and scientific innovation.
• Broaden distribution capabilities to expand the installed base of ExPERT products.
• Pursue SPLs with target customers.
• Expand commercial infrastructure.
• Consider opportunistic investments, partnerships, and acquisitions.

Key Dates